Gain-of-function enhancement of IP3 receptor modal gating by familial Alzheimer's disease-linked presenilin mutants in human cells and mouse neurons

Science Signaling

Volumn 3, Issue 114, 2010, Pages

  Cheung, King Ho ^a   Mei, Lijuan ^a   Mak, Don On Daniel ^a   Hayashi, Ikuo ^b   Iwatsubo, Takeshi ^b   Kang, David E ^c   Foskett, J Kevin ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CALCIUM RELEASE ACTIVATED CALCIUM CHANNEL; INOSITOL TRISPHOSPHATE RECEPTOR; MEMBRANE PROTEIN; MUTANT PROTEIN; PRESENILIN 1; PRESENILIN 2; SECRETASE; UNCLASSIFIED DRUG; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; PRESENILIN; PSEN1 PROTEIN, HUMAN; PSEN2 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; B LYMPHOCYTE; BRAIN CELL; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CHANNEL GATING; CONTROLLED STUDY; ENZYME ACTIVITY; FAMILIAL DISEASE; FRONTOTEMPORAL DEMENTIA; GAIN OF FUNCTION ENHANCEMENT; GENE MUTATION; HUMAN; HUMAN CELL; LYMPHOBLAST; MOLECULAR MECHANICS; MOUSE; NERVE CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; CALCIUM SIGNALING; GENETICS; IN VITRO STUDY; METABOLISM; MUTATION;

MUS;

ALZHEIMER DISEASE; ANIMALS; B-LYMPHOCYTES; CALCIUM SIGNALING; HUMANS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; ION CHANNEL GATING; MICE; MODELS, NEUROLOGICAL; MUTATION; NEURONS; PRESENILIN-1; PRESENILIN-2; PRESENILINS; RECOMBINANT PROTEINS;

EID: 77953644150     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2000818     Document Type: Article

References (63)

1. M. Hutton, J. Hardy, The presenilins and Alzheimer's disease. Hum. Mol. Genet. 6, 1639-1646 (1997).
2. J. Hardy, A hundred years of Alzheimer's disease research. Neuron 52, 3-13 (2006).
3. F. M. LaFerla, S. Oddo, Alzheimer's disease: Ab, tau and synaptic dysfunction. Trends Mol. Med. 11, 170-176 (2005)
4. M. P. Mattson, Pathways towards and away from Alzheimer's disease. Nature 430, 631-639 (2004).
5. W. G. Annaert, L. Levesque, K. Craessaerts, I. Dierinck, G. Snellings, D. Westaway, P. S. George-Hyslop, B. Cordell, P. Fraser, B. De Strooper, Presenilin 1 controls g-secretase processing of amyloid precursor protein in pre-Golgi compartments of hippocampal neurons. J. Cell Biol. 147, 277-294 (1999)
6. B. De Strooper, P. Saftig, K. Craessaerts, H. Vanderstichele, G. Guhde, W. Annaert, K. Von Figura, F. Van Leuven, Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387-390 (1998).
7. H. Li, M. S. Wolfe, D. J. Selkoe, Toward structural elucidation of the g-secretase complex. Structure 17, 326-334 (2009).
8. W. Xia, J. Zhang, D. Kholodenko, M. Citron, M. B. Podlisny, D. B. Teplow, C. Haass, P. Seubert, E. H. Koo, D. J. Selkoe, Enhanced production and oligomerization of the 42-residue amyloid b-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J. Biol. Chem. 272, 7977-7982 (1997)
9. C. Haass, D. J. Selkoe, Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid b-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112 (2007)
10. J. Hardy, D. J. Selkoe, The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356 (2002).
11. C. T. Kelleher, R. Chiu, H. Shin, I. E. Bosdet, M. I. Krzywinski, C. D. Fjell, J. Wilkin, T. Yin, S. P. DiFazio, J. Ali, J. K. Asano, S. Chan, A. Cloutier, N. Girn, S. Leach, D. Lee, C. A. Mathewson, T. Olson, K. O'Connor, A. L. Prabhu, D. E. Smailus, J. M. Stott, M. Tsai, N. H. Wye, G. S. Yang, J. Zhuang, R. A. Holt, N. H. Putnam, J. Vrebalov, J. J. Giovannoni, J. Grimwood, J. Schmutz, D. Rokhsar, S. J. Jones, M. A. Marra, G. A. Tuskan, J. Bohlmann, B. E. Ellis, K. Ritland, C. J. Douglas, J. E. Schein, A physical map of the highly heterozygous Populus genome: Integration with the genome sequence and genetic map and analysis of haplotype variation. Plant J. 50, 1063-1078 (2007)
12. F. M. LaFerla, Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat. Rev. Neurosci. 3, 862-872 (2002)
13. I. F. Smith, K. N. Green, F. M. LaFerla, Calcium dysregulation in Alzheimer's disease: Recent advances gained from genetically modified animals. Cell Calcium 38, 427-437 (2005).
14. H. M. Huang, H. C. Ou, S. J. Hsueh, Amyloid b peptide enhanced bradykinin-mediated inositol (1, 4, 5) trisphosphate formation and cytosolic free calcium. Life Sci. 63, 195-203 (1998).
15. 2+] in hippocampal neurons. Neuroreport 9, 1553-1558 (1998).
16. J. D. Buxbaum, A. A. Ruefli, C. A. Parker, A. M. Cypess, P. Greengard, Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner. Proc. Natl. Acad. Sci. U. S. A. 91, 4489-4493 (1994)
17. K. V. Kuchibhotla, S. T. Goldman, C. R. Lattarulo, H. Y. Wu, B. T. Hyman, B. J. Bacskai, Ab plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 59, 214-225 (2008).
18. J. Herms, I. Schneider, I. Dewachter, N. Caluwaerts, H. Kretzschmar, F. Van Leuven, Capacitive calcium entry is directly attenuated by mutant presenilin-1, independent of the expression of the amyloid precursor protein. J. Biol. Chem. 278, 2484-2489 (2003)
19. M. A. Leissring, Y. Akbari, C. M. Fanger, M. D. Cahalan, M. P. Mattson, F. M. LaFerla, Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice. J. Cell Biol. 149, 793-798 (2000)
20. A. S. Yoo, I. Cheng, S. Chung, T. Z. Grenfell, H. Lee, E. Pack-Chung, M. Handler, J. Shen, W. Xia, G. Tesco, A. J. Saunders, K. Ding, M. P. Frosch, R. E. Tanzi, T. W. Kim, Presenilin-mediated modulation of capacitative calcium entry. Neuron 27, 561-572 (2000).
21. M. A. Leissring, B. A. Paul, I. Parker, C. W. Cotman, F. M. LaFerla, Alzheimer's presenilin-1 mutation potentiates inositol 1, 4, 5-trisphosphate-mediated calcium signaling in Xenopus oocytes. J. Neurochem. 72, 1061-1068 (1999)
22. I. F. Smith, B. Hitt, K. N. Green, S. Oddo, F. M. LaFerla, Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of Alzheimer's disease. J. Neurochem. 94, 1711-1718 (2005).
23. G. E. Stutzmann, Calcium dysregulation, IP3 signaling, and Alzheimer's disease. Neuroscientist 11, 110-115 (2005).
24. 2+ signals and altered membrane excitability. J. Neurosci. 24, 508-513 (2004).
25. K. N. Green, A. Demuro, Y. Akbari, B. D. Hitt, I. F. Smith, I. Parker, F. M. LaFerla, SERCA pump activity is physiologically regulated by presenilin and regulates amyloid b production. J. Cell Biol. 181, 1107-1116 (2008)
26. 2+ leak function of presenilin 1. J. Clin. Invest. 117, 1230-1239 (2007)
27. 2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. Cell 126, 981-993 (2006).
28. S. Chakroborty, I. Goussakov, M. B. Miller, G. E. Stutzmann, Deviant ryanodine receptormediated calcium release resets synaptic homeostasis in presymptomatic 3xTg-AD mice. J. Neurosci. 29, 9458-9470 (2009)
29. 2+ disruptions in young, adult, and aged Alzheimer's disease mice. J. Neurosci. 26, 5180-5189 (2006)
30. R. Etcheberrigaray, N. Hirashima, L. Nee, J. Prince, S. Govoni, M. Racchi, R. E. Tanzi, D. L. Alkon, Calcium responses in fibroblasts from asymptomatic members of Alzheimer's disease families. Neurobiol. Dis. 5, 37-45 (1998) (Pubitemid 28361650)
31. N. Hirashima, R. Etcheberrigaray, S. Bergamaschi, M. Racchi, F. Battaini, G. Binetti, S. Govoni, D. L. Alkon, Calcium responses in human fibroblasts: A diagnostic molecular profile for Alzheimer's disease. Neurobiol. Aging 17, 549-555 (1996).
32. 2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 91, 534-538 (1994)
33. M. A. Leissring, F. M. LaFerla, N. Callamaras, I. Parker, Subcellular mechanisms of presenilin-mediated enhancement of calcium signaling. Neurobiol. Dis. 8, 469-478 (2001)
34. S. L. Chan, M. Mayne, C. P. Holden, J. D. Geiger, M. P. Mattson, Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J. Biol. Chem. 275, 18195-18200 (2000)
35. 2+ content in presenilin double knock-out cells. Cell Calcium 40, 41-51 (2006).
36. G. E. Stutzmann, I. Smith, A. Caccamo, S. Oddo, I. Parker, F. Laferla, Enhanced ryanodinemediated calcium release in mutant PS1-expressing Alzheimer's mouse models. Ann. N. Y. Acad. Sci. 1097, 265-277 (2007)
37. 3 receptor channel gating. Neuron 58, 871-883 (2008).
38. A. Tandon, P. Fraser, The presenilins. Genome Biol. 3, reviews 3014. 1-reviews 3014. 9 (2002).
39. B. Dermaut, S. Kumar-Singh, S. Engelborghs, J. Theuns, R. Rademakers, J. Saerens, B. A. Pickut, K. Peeters, M. van den Broeck, K. Vennekens, S. Claes, M. Cruts, P. Cras, J. J. Martin, C. Van Broeckhoven, P. P. De Deyn, A novel presenilin 1 mutation associated with Pick's disease but not b-amyloid plaques. Ann. Neurol. 55, 617-626 (2004)
40. G. Raux, R. Gantier, C. Thomas-Anterion, J. Boulliat, P. Verpillat, D. Hannequin, A. Brice, T. Frebourg, D. Campion, Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation. Neurology 55, 1577-1578 (2000).
41. These are amino acid substitutions at particular residues. Abbreviations for the amino acid residues are as follows: A, Ala; D, Asp; G, Gly; I, Ile; L, Leu; M, Met; N, Asn; P, Pro; and V, Val.
42. 2+ release. J. Physiol. 573, 645-662 (2006)
43. L. Ionescu, C. White, K. H. Cheung, J. Shuai, I. Parker, J. E. Pearson, J. K. Foskett, D. O. Mak, Mode switching is the major mechanism of ligand regulation of InsP3 receptor calcium release channels. J. Gen. Physiol. 130, 631-645 (2007)
44. C. Li, X. Wang, H. Vais, C. B. Thompson, J. K. Foskett, C. White, Apoptosis regulation by Bcl-xL modulation of mammalian inositol 1, 4, 5-trisphosphate receptor channel isoform gating. Proc. Natl. Acad. Sci. U. S. A. 104, 12565-12570 (2007)
45. 2+ signalling in cultured rat myotubes, isolated myonuclei, and neuroblastoma (NG108-15) cells. FEBS Lett. 579, 2051-2057 (2005)
46. 3R. Nat. Cell Biol. 7, 1021-1028 (2005)
47. + lymphocytes in Alzheimer's disease and in older persons with Down's syndrome. Neurobiol. Aging 14, 177-185 (1993).
48. S. Oddo, A. Caccamo, J. D. Shepherd, M. P. Murphy, T. E. Golde, R. Kayed, R. Metherate, M. P. Mattson, Y. Akbari, F. M. LaFerla, Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Ab and synaptic dysfunction. Neuron 39, 409-421 (2003).
49. D. E. Kang, S. Soriano, X. Xia, C. G. Eberhart, B. De Strooper, H. Zheng, E. H. Koo, Presenilin couples the paired phosphorylation of β-catenin independent of axin: Implications for β-catenin activation in tumorigenesis. Cell 110, 751-762 (2002).
50. E. Repetto, I. S. Yoon, H. Zheng, D. E. Kang, Presenilin 1 regulates epidermal growth factor receptor turnover and signaling in the endosomal-lysosomal pathway. J. Biol. Chem. 282, 31504-31516 (2007)
51. 2+ release channels. Physiol. Rev. 87, 593-658 (2007)
52. K. N. Green, F. M. LaFerla, Linking calcium to Ab and Alzheimer's disease. Neuron 59, 190-194 (2008).
53. M. Hayley, S. Perspicace, T. Schulthess, J. Seelig, Calcium enhances the proteolytic activity of BACE1: An in vitro biophysical and biochemical characterization of the BACE1-calcium interaction. Biochim. Biophys. Acta 1788, 1933-1938 (2009).
54. N. Pierrot, S. F. Santos, C. Feyt, M. Morel, J. P. Brion, J. N. Octave, Calcium-mediated transient phosphorylation of tau and amyloid precursor protein followed by intraneuronal amyloid-b accumulation. J. Biol. Chem. 281, 39907-39914 (2006)
55. H. W. Querfurth, D. J. Selkoe, Calcium ionophore increases amyloid b peptide production by cultured cells. Biochemistry 33, 4550-4561 (1994).
56. M. P. Mattson, Antigenic changes similar to those seen in neurofibrillary tangles are elicited by glutamate and Ca2+ influx in cultured hippocampal neurons. Neuron 4, 105-117 (1990).
57. M. P. Mattson, M. A. Lovell, W. D. Ehmann, W. R. Markesbery, Comparison of the effects of elevated intracellular aluminum and calcium levels on neuronal survival and tau immunoreactivity. Brain Res. 602, 21-31 (1993)
58. D. E. Kang, S. Soriano, M. P. Frosch, T. Collins, S. Naruse, S. S. Sisodia, G. Leibowitz, F. Levine, E. H. Koo, Presenilin 1 facilitates the constitutive turnover of b-catenin: Differential activity of Alzheimer's disease-linked PS1 mutants in the b-catenin-signaling pathway. J. Neurosci. 19, 4229-4237 (1999)
59. D. E. Kang, I. S. Yoon, E. Repetto, T. Busse, N. Yermian, L. Ie, E. H. Koo, Presenilins mediate phosphatidylinositol 3-kinase/AKT and ERK activation via select signaling receptors. Selectivity of PS2 in platelet-derived growth factor signaling. J. Biol. Chem. 280, 31537-31547 (2005).
60. F. Qin, A. Auerbach, F. Sachs, Hidden Markov modeling for single channel kinetics with filtering and correlated noise. Biophys. J. 79, 1928-1944 (2000)
61. F. Qin, A. Auerbach, F. Sachs, A direct optimization approach to hidden Markov modeling for single channel kinetics. Biophys. J. 79, 1915-1927 (2000).
62. K. L. Magleby, B. S. Pallotta, Burst kinetics of single calcium-activated potassium channels in cultured rat muscle. J. Physiol. 344, 605-623 (1983)
63. Acknowledgments: We thank R. Eckenhoff and H. Wei for supplying mice, and D. Shilling for assistance with the culturing of the PS DKO MEF cells. Funding: Acknowledgement is made to the donors of Alzheimer's Disease Research, a program of the American Health Assistance Foundation (A2008-137 to J. K. F.), to the Alzheimer's Association (IIRG-08-91662 to D. E. K), and to the Japan Science and Technology Agency (T. I.). Author contributions: K.-H. C. designed and performed the experiments, analyzed data, and wrote the manuscript. L. M. developed recombinant baculoviruses and performed infections, transfections, and cell culture. D.-O. D. M. developed software for modal gating and single-cell Ca2+ analyses and assisted in the analyses. I. H. and T. I. developed recombinant baculoviral PS constructs. D. E. K. developed DKO MEF cells. J. K. F. designed and analyzed experiments and wrote the manuscript. Competing interest: None of the authors have competing interests.